Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

Odia Y, Koschmann C, Vitanza NA, de Blank P, Aguilera D, Allen J, Daghistani D, Hall M, Khatib Z, Kline C, MacDonald T, Mueller S, Faison SL, Allen JE, Naderer OJ, Ramage SC, Tarapore RS, McGovern SL, Khatua S, Zaky W, Gardner SL

Open source

DOI: 10.1093/neuonc/noae001
Published: 2024 May 3
Container: Neuro-oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noae001,
  title = {Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.},
  author = {Odia Y and Koschmann C and Vitanza NA and de Blank P and Aguilera D and Allen J and Daghistani D and Hall M and Khatib Z and Kline C and MacDonald T and Mueller S and Faison SL and Allen JE and Naderer OJ and Ramage SC and Tarapore RS and McGovern SL and Khatua S and Zaky W and Gardner SL},
  year = {2024},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/noae001},
  url = {https://doi.org/10.1093/neuonc/noae001}
}

RIS

TY  - JOUR
TI  - Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
AU  - Odia Y
AU  - Koschmann C
AU  - Vitanza NA
AU  - de Blank P
AU  - Aguilera D
AU  - Allen J
AU  - Daghistani D
AU  - Hall M
AU  - Khatib Z
AU  - Kline C
AU  - MacDonald T
AU  - Mueller S
AU  - Faison SL
AU  - Allen JE
AU  - Naderer OJ
AU  - Ramage SC
AU  - Tarapore RS
AU  - McGovern SL
AU  - Khatua S
AU  - Zaky W
AU  - Gardner SL
PY  - 2024
JO  - Neuro-oncology
DO  - 10.1093/neuonc/noae001
UR  - https://doi.org/10.1093/neuonc/noae001
ER  -

APA

Y, O., C, K., NA, V., P, D. B., D, A., J, A., D, D., M, H., Z, K., C, K., T, M., S, M., SL, F., JE, A., OJ, N., SC, R., RS, T., SL, M., S, K., W, Z., & SL, G. (2024). Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.. Neuro-oncology. https://doi.org/10.1093/neuonc/noae001

Source records

pubmed · retrieved 2026-09-26T00:33:56.340Z
europe-pmc · retrieved 2026-09-26T00:33:56.351Z